Core Insights - Innoviz Technologies Ltd. reported a quarterly loss of $0.09 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.08, but an improvement from a loss of $0.13 per share a year ago [1] - The company posted revenues of $9.75 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 19.38%, compared to revenues of $6.66 million in the same quarter last year [2] - The stock has gained approximately 8.3% since the beginning of the year, underperforming the S&P 500's gain of 9.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $13.79 million, and for the current fiscal year, it is -$0.27 on revenues of $59.63 million [7] - The estimate revisions trend for Innoviz Technologies was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Automotive - Original Equipment industry, to which Innoviz Technologies belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

分组1 - Gladstone Investment (GAIN) reported quarterly earnings of $0.24 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, with an earnings surprise of +4.35% [1] - The company posted revenues of $23.54 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.68%, compared to year-ago revenues of $22.18 million [2] - Over the last four quarters, Gladstone Investment has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] 分组2 - The stock has gained approximately 7.7% since the beginning of the year, while the S&P 500 has increased by 8.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the coming quarter is $0.23 on $24.35 million in revenues, and $0.89 on $97.14 million in revenues for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Financial - SBIC & Commercial Industry is currently in the bottom 27% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The estimate revisions trend for Gladstone Investment was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Core Insights - Southland Holdings (SLND) reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.96 per share a year ago, resulting in an earnings surprise of +32.14% [1] - The company posted revenues of $215.38 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 9.08%, and down from $251.51 million year-over-year [2] - Southland shares have increased by approximately 38.2% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $247.7 million, and for the current fiscal year, it is -$0.68 on revenues of $972.9 million [7] - The estimate revisions trend for Southland was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Building Products - Miscellaneous industry, to which Southland belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Metagenomi reported a quarterly loss of $0.54 per share, better than the Zacks Consensus Estimate of a loss of $0.68, but worse than a loss of $0.29 per share a year ago, representing an earnings surprise of +20.59% [1] - The company posted revenues of $8.51 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 20.50%, but down from $20.01 million in the same quarter last year [2] - Over the last four quarters, Metagenomi has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Metagenomi shares have declined approximately 49.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] - The current Zacks Rank for Metagenomi is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $7.07 million, and for the current fiscal year, it is -$2.48 on revenues of $32.4 million [7] - The outlook for the Medical - Drugs industry, where Metagenomi operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Company Performance - WideOpenWest reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, and compared to a loss of $0.13 per share a year ago, indicating an earnings surprise of -46.67% [1] - The company posted revenues of $144.2 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.14%, but down from $158.8 million in the same quarter last year [2] - Over the last four quarters, WideOpenWest has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] Stock Performance - WideOpenWest shares have declined approximately 35.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $141.3 million, and for the current fiscal year, it is -$0.78 on revenues of $574.9 million [7] Industry Outlook - The Cable Television industry, to which WideOpenWest belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting a challenging environment for the company [8] - The performance of WideOpenWest's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - MidCap Financial Investment (MFIC) reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, but down from $0.45 per share a year ago, indicating a mixed performance in earnings despite a positive surprise this quarter [1][2]. Financial Performance - The company posted revenues of $81.25 million for the quarter ended June 2025, which missed the Zacks Consensus Estimate by 0.5% and represents an increase from $69.16 million year-over-year [2]. - Over the last four quarters, MidCap Financial has surpassed consensus EPS estimates two times, but has not beaten consensus revenue estimates during the same period [2]. Stock Performance - MidCap Financial shares have declined approximately 6.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3]. - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $82.39 million, and for the current fiscal year, it is $1.50 on revenues of $325.08 million [7]. Industry Outlook - The Financial - Miscellaneous Services industry, to which MidCap Financial belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]. - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact MidCap Financial's stock performance [5].

Core Viewpoint - Agenus reported a quarterly loss of $1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.78, but an improvement from a loss of $2.52 per share a year ago [1] Financial Performance - The company posted revenues of $25.7 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.68% and showing an increase from $23.51 million in the same quarter last year [2] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Agenus shares have increased approximately 75.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimate for the coming quarter at -$0.20 on revenues of $24.97 million, and for the current fiscal year at $1.56 on revenues of $246.08 million [7] - The estimate revisions trend for Agenus was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Agenus belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - Enanta Pharmaceuticals reported a quarterly loss of $0.85 per share, which was better than the Zacks Consensus Estimate of a loss of $1.25, representing an earnings surprise of +32.00% [1] - The company posted revenues of $18.31 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 21.29% and showing an increase from $17.97 million in the same quarter last year [2] - Over the last four quarters, Enanta has surpassed consensus EPS estimates two times and topped revenue estimates twice [2] Stock Movement and Outlook - Enanta Pharmaceuticals shares have increased by approximately 20% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$1.21 on revenues of $15.35 million, and for the current fiscal year, it is -$4.33 on revenues of $62.35 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Enanta belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Enanta's stock may also be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Core Scientific, Inc. reported a quarterly loss of $0.04 per share, outperforming the Zacks Consensus Estimate of a loss of $0.07, indicating a positive earnings surprise of +42.86% [1] - The company generated revenues of $78.63 million for the quarter ended June 2025, which was 2.28% below the Zacks Consensus Estimate and a significant decrease from $141.1 million in the same quarter last year [2] Financial Performance - Over the last four quarters, Core Scientific has exceeded consensus EPS estimates three times and topped revenue estimates twice [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $111.86 million, while for the current fiscal year, the estimate is $1.44 on revenues of $412.08 million [7] Market Position - Core Scientific shares have increased by approximately 2.1% since the beginning of the year, underperforming compared to the S&P 500's gain of 7.8% [3] - The company currently holds a Zacks Rank of 3 (Hold), suggesting that its shares are expected to perform in line with the market in the near future [6] Industry Outlook - The Financial - Miscellaneous Services industry, to which Core Scientific belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Core Scientific's stock performance [5]

Company Performance - Morgan Stanley Direct Lending Fund reported quarterly earnings of $0.5 per share, missing the Zacks Consensus Estimate of $0.52 per share, and down from $0.63 per share a year ago, representing an earnings surprise of -3.85% [1] - The company posted revenues of $99.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.29%, and down from $104.19 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - Morgan Stanley Direct Lending Fund shares have lost about 10.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.52 on revenues of $98.69 million, and for the current fiscal year, it is $2.08 on revenues of $396.8 million [7] - The outlook for the industry can significantly impact the stock's performance, with the Financial - SBIC & Commercial Industry currently in the bottom 42% of Zacks industries [8]